TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06043466: Phase I Clinical Study of Chimeric Antigen Receptor T Cells (C-13-60) in the Treatment of Carcinoembryonic Antigen (CEA) Positive Advanced Malignant Solid Tumors

Sponsor: Chongqing Precision Biotech Co., Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,100,016

Rescue Site Savings

+$4,680,984

Unlock Full NCT06043466 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06043466 Rescue Dossier →